Chimeric antigen receptor (CAR) T cell therapy has significantly improved the outlook for patients with certain types of poor-risk lymphoma. Despite these advances, a majority undergoing CAR will suffer progression or relapse disease, and toxicity remains concern. Additionally, disease subtypes that are most likely to benefit from have yet be fully defined. Many ongoing trials exploring novel a...